Jonathan Angotti, MD
Pulmonary Disease · Maryville, TNNPI 1487033387
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,645 of the $2,264 with a category attached, or 72.7%. 22 manufacturers reported payments, led by Veran Medical Technologies, Inc. at 33.5% of the total. Reporting peaked in 2022 at $950 and has fallen 97.7% since, to $22 in 2025. That places this record below the midpoint for pulmonary disease clinicians in TN, where the typical reported total is $3,628.
Across 83 payments — averaging $27.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veran Medical Technologies, Inc.$759
- GSK$278
- AstraZeneca$188
- Genentech USA, Inc.$126
- Boehringer Ingelheim$110
- Grifols USA, LLC$110
- plus $693 from 16 others
What the payments were for
- Travel & lodging$60327%
- Food & beverage$1,64573%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veran Medical Technologies, Inc. | 3 | $759 |
| GSK | 20 | $278 |
| AstraZeneca | 5 | $188 |
| Genentech USA, Inc. | 7 | $126 |
| Boehringer Ingelheim | 6 | $110 |
| Grifols USA, LLC | 6 | $110 |
| Insmed, Inc. | 5 | $99 |
| Baxter Healthcare | 3 | $80 |
| Regeneron Healthcare Solutions, Inc. | 4 | $70 |
| United Therapeutics Corporation | 3 | $67 |
| Sanofi | 3 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $61 |
| Inogen, Inc. | 2 | $37 |
| Mylan Specialty L.p. | 2 | $35 |
| Electromed, Inc. | 2 | $34 |
| Advanced Respiratory, Inc | 2 | $33 |
| AbbVie | 2 | $30 |
| Pfizer | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Nabriva Therapeutics, PLC | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,264 in reported general payments places this provider in the 40th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Maryville
- Bruce RobertsMaryville$18K
- Michael RamosMaryville$15K
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
- Otis RickmanNashville$392K
- Michael CzarneckiChattanooga$348K
- Susan GarwoodNashville$343K
- Girendra HoskereBristol$285K
- Carlos BaleeiroChattanooga$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.